Recruiting
Chronic graft versus host disease
RecruitingStudy of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy
Registered drugNo placebo
Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy
Registered drugNo placebo
- Disease:Chronic graft versus host disease
- Substances:BelumosudilBortezomib+9
Countries:
Austria
Austria- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Belumosudil



